Bhagyalalitha Meduri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bhagyalalitha Meduri has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Gurubasavaraj Veeranna Pujar
JSS Academy of Higher Education & Research
4 shared publications - Akshatha Handattu Shankaranarayana
Computer Aided Drug Design Laboratory, Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Sri Shivarathreeshwara Nagara, Mysuru, 570015, India
3 shared publications - Manisha Singh
Computer Aided Drug Design Laboratory, Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Sri Shivarathreeshwara Nagara, Mysuru, 570015, India
3 shared publications - Durgesh Paresh Bidye
Computer Aided Drug Design Laboratory, Department of Pharmaceutical Chemistry, JSS College of Pharmacy Mysore, JSS Academy of Higher Education and Research, Mysore, Karnataka, 570015, India
2 shared publications - Karthik G. Pujar
Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research (JSS AHER), Mysuru – 570015, Karnataka, India
2 shared publications - Sethu Arun Kumar
Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Sri Shivarathreeshwara Nagara, Mysuru-570015, India
2 shared publications
Latest Publications
- 5 April 2024
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 16 (8) , 769-790
Design, synthesis and evaluation of new thiazolidin-4-ones as LPA 1 receptor antagonists for breast cancer therapy
Aim: Breast cancer has been a leading cause of mortality among women worldwide in recent years. Targeting the lysophosphatidic acid (LPA)–LPA1 pathway using small molecules could improve breast can... Plain language summary Breast cancer is a major cause of death for women worldwide. Using small molecules to target the lysophosphatidic acid (LPA)–LPA1 pathway could improve breast cancer treatmen... Tweetable abstract New thiazolidin-4-ones were tested on MCF-7 cells; active compounds were analyzed for effects on apoptosis, migration, angiogenesis and LPA1 expression. TZ-4 and TZ-6 reduced MCF... Graphical abstract Novel thiazolidin-4-ones as LPA1 inhibitors and their subsequent effects.
- 5 April 2024
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 16 (8) , 769-790
Design, synthesis and evaluation of new thiazolidin-4-ones as LPA 1 receptor antagonists for breast cancer therapy
Aim: Breast cancer has been a leading cause of mortality among women worldwide in recent years. Targeting the lysophosphatidic acid (LPA)–LPA1 pathway using small molecules could improve breast can... Plain language summary Breast cancer is a major cause of death for women worldwide. Using small molecules to target the lysophosphatidic acid (LPA)–LPA1 pathway could improve breast cancer treatmen... Tweetable abstract New thiazolidin-4-ones were tested on MCF-7 cells; active compounds were analyzed for effects on apoptosis, migration, angiogenesis and LPA1 expression. TZ-4 and TZ-6 reduced MCF... Graphical abstract Novel thiazolidin-4-ones as LPA1 inhibitors and their subsequent effects.
- 27 October 2023
- Published by Wiley in Chemistry & Biodiversity
- Vol. 20 (11) , e202300971
Novel Antitubercular Agents: Design, Synthesis, Molecular Dynamic and Biological Studies of Pyrazole – 1,2,4‐Triazole Conjugates
Mycobacterium tuberculosis (Mtb) has numerous cell wall and non‐cell wall mediated receptors for drug action, of which cell wall mediated targets were found to be more promising because of their pivotal role in bacterial protection and survival. Herein, we reported the design and synthesis of a series of pyrazole‐linked triazoles based on the reported structural features of promising drug candidates that target DprE1 receptors through a Structure‐based drug design (SBDD) approach (6a–6j and 7a–7j). The synthesized compounds were evaluated for their in‐vitro antitubercular activity against virulent strains of Mtb H37Rv. In‐silico studies revealed that most compounds exhibit binding interactions with crucial amino acids like Lys418, Tyr314, Tyr60, and Asp386 at DprE1. Furthermore, the protein‐ligand (7j) shows appreciable stability compared to innate protein in a 100 ns molecular dynamic simulation study. In‐vitro MAB assay revealed that 14 compounds exhibit significant antitubercular activity with minimum inhibitory concentration (MIC) of the 3.15–4.87 μM of the 20 compounds tested. An in‐vitro cytotoxicity study on normal cell lines (MCF10) revealed safe compounds (IC50 values:341.85 to 726.08 μM). Hence, the present study opens the development of new pyrazole‐linked triazoles as probable DprE1 inhibitors.
- 27 October 2023
- Published by Wiley in Chemistry & Biodiversity
- Vol. 20 (11) , e202300971
Novel Antitubercular Agents: Design, Synthesis, Molecular Dynamic and Biological Studies of Pyrazole – 1,2,4‐Triazole Conjugates
Mycobacterium tuberculosis (Mtb) has numerous cell wall and non‐cell wall mediated receptors for drug action, of which cell wall mediated targets were found to be more promising because of their pivotal role in bacterial protection and survival. Herein, we reported the design and synthesis of a series of pyrazole‐linked triazoles based on the reported structural features of promising drug candidates that target DprE1 receptors through a Structure‐based drug design (SBDD) approach (6a–6j and 7a–7j). The synthesized compounds were evaluated for their in‐vitro antitubercular activity against virulent strains of Mtb H37Rv. In‐silico studies revealed that most compounds exhibit binding interactions with crucial amino acids like Lys418, Tyr314, Tyr60, and Asp386 at DprE1. Furthermore, the protein‐ligand (7j) shows appreciable stability compared to innate protein in a 100 ns molecular dynamic simulation study. In‐vitro MAB assay revealed that 14 compounds exhibit significant antitubercular activity with minimum inhibitory concentration (MIC) of the 3.15–4.87 μM of the 20 compounds tested. An in‐vitro cytotoxicity study on normal cell lines (MCF10) revealed safe compounds (IC50 values:341.85 to 726.08 μM). Hence, the present study opens the development of new pyrazole‐linked triazoles as probable DprE1 inhibitors.
- 25 October 2023
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 15 (22) , 2087-2112
Restoration of p53 Functions By Suppression of mortalin–p53 Sequestration: an Emerging Target in Cancer Therapy
Functional inactivation of wild-type p53 is a major trait of cancerous cells. In many cases, such inactivation occurs by either TP53 gene mutations or due to overexpression of p53 binding partners.... Graphical abstract
- 25 October 2023
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 15 (22) , 2087-2112
Restoration of p53 Functions By Suppression of mortalin–p53 Sequestration: an Emerging Target in Cancer Therapy
Functional inactivation of wild-type p53 is a major trait of cancerous cells. In many cases, such inactivation occurs by either TP53 gene mutations or due to overexpression of p53 binding partners.... Graphical abstract
- 1 October 2021
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 222, 113574
Lysophosphatidic acid (LPA) receptor modulators: Structural features and recent development
- 1 October 2021
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 222, 113574
Lysophosphatidic acid (LPA) receptor modulators: Structural features and recent development